Opinion|Videos|March 1, 2024
Future Perspectives on HER2+ Breast Cancer Treatment
Author(s)Carey K. Anders, MD
Carey K. Anders, MD, concludes with a look toward the future of HER2+ breast cancer treatment and provides advice to community oncologists treating patients with breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
5